MX392383B - Metodos para tratar afecciones oculares. - Google Patents

Metodos para tratar afecciones oculares.

Info

Publication number
MX392383B
MX392383B MX2017005064A MX2017005064A MX392383B MX 392383 B MX392383 B MX 392383B MX 2017005064 A MX2017005064 A MX 2017005064A MX 2017005064 A MX2017005064 A MX 2017005064A MX 392383 B MX392383 B MX 392383B
Authority
MX
Mexico
Prior art keywords
methods
eye conditions
treating eye
treating
conditions
Prior art date
Application number
MX2017005064A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005064A (es
Inventor
Douglas Michael Ackermann Jr
James Loudin
Kenneth J Mandell
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX392383(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of MX2017005064A publication Critical patent/MX2017005064A/es
Publication of MX392383B publication Critical patent/MX392383B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
MX2017005064A 2014-10-20 2015-10-19 Metodos para tratar afecciones oculares. MX392383B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07
PCT/US2015/056273 WO2016064759A1 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
MX2017005064A MX2017005064A (es) 2018-02-23
MX392383B true MX392383B (es) 2025-03-24

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005064A MX392383B (es) 2014-10-20 2015-10-19 Metodos para tratar afecciones oculares.
MX2022005888A MX2022005888A (es) 2014-10-20 2017-04-19 Metodos para tratar afecciones oculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005888A MX2022005888A (es) 2014-10-20 2017-04-19 Metodos para tratar afecciones oculares.

Country Status (21)

Country Link
US (14) US9504644B2 (cg-RX-API-DMAC7.html)
EP (3) EP4413974A3 (cg-RX-API-DMAC7.html)
JP (3) JP6873906B2 (cg-RX-API-DMAC7.html)
KR (2) KR102601505B1 (cg-RX-API-DMAC7.html)
CN (3) CN107106542B (cg-RX-API-DMAC7.html)
AU (2) AU2015336216B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022025737B1 (cg-RX-API-DMAC7.html)
CA (1) CA2965129C (cg-RX-API-DMAC7.html)
DK (2) DK3848028T5 (cg-RX-API-DMAC7.html)
EA (1) EA035335B1 (cg-RX-API-DMAC7.html)
ES (2) ES2848977T5 (cg-RX-API-DMAC7.html)
FI (1) FI3848028T3 (cg-RX-API-DMAC7.html)
IL (3) IL293188B2 (cg-RX-API-DMAC7.html)
MX (2) MX392383B (cg-RX-API-DMAC7.html)
MY (1) MY186870A (cg-RX-API-DMAC7.html)
PH (1) PH12017500602A1 (cg-RX-API-DMAC7.html)
PL (1) PL3848028T3 (cg-RX-API-DMAC7.html)
PT (2) PT3848028T (cg-RX-API-DMAC7.html)
SG (2) SG10202011669PA (cg-RX-API-DMAC7.html)
WO (1) WO2016064759A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703467B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102601505B1 (ko) 2014-10-20 2023-11-14 오이스터 포인트 파마 인코포레이티드 안과 질환의 치료 방법
ES2893126T3 (es) * 2016-04-07 2022-02-08 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
EP3820443A1 (en) * 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
JP4196829B2 (ja) 2001-11-29 2008-12-17 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンのコハク酸塩およびその医薬組成物
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2006040680A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
EP1809238B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Ophthalmic emulsions containing an immunosuppressive agent
AU2006226509A1 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
AU2006282799B2 (en) 2005-08-26 2012-11-29 Healthpartners Research & Education Methods for treatment of headaches by administration of oxytocin
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
PT2114970E (pt) * 2007-02-02 2011-09-22 Pfizer Prod Inc Compostos tricíclicos e sua utilização como moduladores de receptor de glucocorticóide
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
AU2009221860A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
EP2344496A1 (en) * 2008-09-05 2011-07-20 Targacept Inc. Amides of diazabicyclooctanes and uses thereof
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PE20110589A1 (es) 2008-12-01 2011-09-07 Targacept Inc Formas cristalinas del compuesto (r)-5-((e)-2-(pirrolidin-3-ilvinil)pirimidina
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CA2841416A1 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
US20140128606A1 (en) * 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
CA2852268C (en) * 2011-10-20 2020-08-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
WO2013080196A1 (en) * 2011-11-30 2013-06-06 D.E.S. Diagnostics Ltd. Dry eye diagnostic
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
AU2014239842B2 (en) 2013-03-15 2018-07-19 Glia, Llc Cranial delivery of pharmaceuticals
HK1220934A1 (zh) 2013-04-19 2017-05-19 Oculeve, Inc. 鼻刺激装置和方法
KR102601505B1 (ko) 2014-10-20 2023-11-14 오이스터 포인트 파마 인코포레이티드 안과 질환의 치료 방법
ES2893126T3 (es) 2016-04-07 2022-02-08 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions

Also Published As

Publication number Publication date
AU2020213351A1 (en) 2020-08-27
EA201790893A1 (ru) 2018-01-31
EP3848028B9 (en) 2024-10-16
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
ES2848977T5 (es) 2024-06-06
MX2017005064A (es) 2018-02-23
CN111956803B (zh) 2025-10-31
MX2022005888A (es) 2022-06-14
US20240173318A1 (en) 2024-05-30
BR122022025737B1 (pt) 2023-12-26
FI3848028T3 (fi) 2024-08-21
US20160106745A1 (en) 2016-04-21
US11903943B2 (en) 2024-02-20
JP6873906B2 (ja) 2021-05-19
CA2965129C (en) 2024-03-12
PH12017500602A1 (en) 2017-09-04
US11903942B2 (en) 2024-02-20
US9597284B2 (en) 2017-03-21
JP7502404B2 (ja) 2024-06-18
CN107106542A (zh) 2017-08-29
DK3848028T3 (da) 2024-08-26
MY186870A (en) 2021-08-26
EP4413974A2 (en) 2024-08-14
KR102511955B1 (ko) 2023-03-22
US20230226053A1 (en) 2023-07-20
ZA201703467B (en) 2023-12-20
EP3848028B1 (en) 2024-05-29
SG11201703135XA (en) 2017-05-30
US10456396B2 (en) 2019-10-29
US20250255865A1 (en) 2025-08-14
EP3848028A1 (en) 2021-07-14
IL293188A (en) 2022-07-01
BR112017008097B1 (pt) 2023-03-28
JP2017531044A (ja) 2017-10-19
US20250275963A1 (en) 2025-09-04
KR102601505B1 (ko) 2023-11-14
IL251769A0 (en) 2017-06-29
EP3209295A4 (en) 2018-05-23
KR20170086040A (ko) 2017-07-25
US9504645B2 (en) 2016-11-29
DK3209295T4 (da) 2024-02-26
ES2986830T3 (es) 2024-11-12
IL293188B1 (en) 2025-02-01
US20170239244A1 (en) 2017-08-24
US20160106665A1 (en) 2016-04-21
US9504644B2 (en) 2016-11-29
US20160106744A1 (en) 2016-04-21
JP7257371B2 (ja) 2023-04-13
CN107106542B (zh) 2020-05-08
DK3848028T5 (da) 2025-01-20
AU2015336216B2 (en) 2020-05-21
US20230226054A1 (en) 2023-07-20
PL3848028T3 (pl) 2024-11-18
SG10202011669PA (en) 2020-12-30
IL293188B2 (en) 2025-06-01
WO2016064759A1 (en) 2016-04-28
US20250235449A1 (en) 2025-07-24
US20200246336A1 (en) 2020-08-06
CN111956650B (zh) 2024-06-04
BR112017008097A2 (pt) 2018-02-20
EA035335B1 (ru) 2020-05-28
EP3209295B2 (en) 2023-12-06
EP3209295B1 (en) 2020-12-09
US11903941B2 (en) 2024-02-20
ES2848977T3 (es) 2021-08-13
US11224598B2 (en) 2022-01-18
EP3209295A1 (en) 2017-08-30
JP2021038250A (ja) 2021-03-11
CN111956650A (zh) 2020-11-20
KR20230042144A (ko) 2023-03-27
PT3209295T (pt) 2021-02-05
US11911380B2 (en) 2024-02-27
US20230226052A1 (en) 2023-07-20
AU2015336216A1 (en) 2017-06-08
IL251769B (en) 2022-06-01
AU2020213351B2 (en) 2023-04-06
US9532944B2 (en) 2017-01-03
IL318427A (en) 2025-03-01
CA2965129A1 (en) 2016-04-28
CN111956803A (zh) 2020-11-20
PT3848028T (pt) 2024-09-20
DK3209295T3 (da) 2021-03-01
JP2023024574A (ja) 2023-02-16
EP4413974A3 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
GB2541571A (en) Pharmaceutical compositions
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
IL246791A0 (en) Compositions and methods for treating eye diseases
MX392383B (es) Metodos para tratar afecciones oculares.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EP3585393A4 (en) FORMULAS FOR EYE TREATMENTS
DK3393579T3 (da) Øjenbehandlingssystem
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
ZA201807438B (en) Methods of treating ocular conditions
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EP3117210A4 (en) Compositions and methods for treating eye infections and disease
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
IL246667A0 (en) Compositions and methods for treatment of abnormal cell growth
EP3277237C0 (fr) Implant ophtalmologique d'interposition
EP3240778A4 (en) Methods and agents for treating disease
IL252707A0 (en) Compositions and methods for treating diseases and conditions
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych